Revenues during 2023 reached NIS 356 million, alongside an Adjusted EBITDA1 of NIS 61 million , as compared to an Adjusted EBITDA of NIS 51 million in our preliminary results.
The Company’s.
Revenues for H2 2023 were affected by damages caused by the terrorist attack on October 7, 2023 and the war in Gaza. However, InterCure it is entitled to full compensation from the Israeli.